A single-arm exploratory study of nimotuzumab added to concurrent chemoradiotherapy has reported high 12-week response rates and preliminary two-year survival estimates in patients with EGFR-expressing locally advanced cervical squamous cell carcinoma, while emphasizing that the absence of a control group prevents any conclusion about whether the antibody actually improved outcomes beyond standard treatment.

The trial design reflected a common challenge in cervical oncology. Concurrent chemoradiotherapy is the standard non-surgical treatment for locally advanced cervical cancer, yet residual disease, recurrence, and distant failure remain clinically relevant problems, and patient-level data describing nimotuzumab combined with this regimen have been limited. Nimotuzumab is a monoclonal antibody directed against EGFR, a receptor frequently expressed on cervical squamous carcinoma cells, and the study tested whether weekly infusions could be layered onto cisplatin-based chemoradiotherapy without unacceptable toxicity.

Screening identified 58 potentially eligible patients, of whom 36 were treated and formed both the full analysis set and the safety set.

The response results were the study’s most striking descriptive finding. Complete response was observed in 18 of the 34 evaluable patients, or 52.9 percent, while partial response occurred in 12 patients, or 35.3 percent. Three patients had stable disease, accounting for 8.8 percent, and one patient experienced progressive disease, or 2.9 percent. Taken together, these figures yielded an objective response rate of 88.2 percent with a 95 percent confidence interval of 73.4 to 95.3, and a disease control rate of 97.1 percent with a 95 percent confidence interval of 85.1 to 99.5.

The investigators also applied a conservative sensitivity analysis to address the two patients who could not be formally evaluated for response. When both non-evaluable patients were counted as nonresponders, the objective response rate fell to 83.3 percent with a 95 percent confidence interval of 68.1 to 92.1. This sensitivity calculation underscores the uncertainty inherent in small cohorts, where the handling of even one or two unevaluable cases can shift the headline percentage by several points.

Survival and disease control estimates came from Kaplan–Meier analyses after a median follow-up of 30.6 months, with an interquartile range of 24.2 to 38.4 months. Progression or death occurred in 8 of the 36 treated patients, representing 22.2 percent of the cohort. The two-year progression-free survival rate was estimated at 83.2 percent with a 95 percent confidence interval of 65.1 to 92.3, the two-year overall survival rate at 97.2 percent with a confidence interval of 81.9 to 99.6, and the two-year locoregional control rate at 88.6 percent with a confidence interval of 71.2 to 95.8. Median progression-free survival and median overall survival had not been reached at the time of analysis.

Because 10 patients in the cohort received adjuvant chemotherapy after the combined regimen, the researchers performed an additional analysis excluding these individuals. In that restricted group, the two-year progression-free survival estimate was 81.7 percent, only modestly lower than the full-cohort figure. This secondary estimate suggests that the overall survival and disease control patterns were not driven solely by the subgroup that received additional post-treatment therapy, although the numbers remain too small for firm conclusions.

Safety data indicated that the regimen was deliverable in practice. Any-grade adverse events occurred in 33 of the 36 treated patients, or 91.7 percent, a figure consistent with the known toxicity profile of concurrent chemoradiotherapy itself. Grade 3 or higher adverse events affected 13 patients, or 36.1 percent, and serious adverse events were recorded in 3 patients, or 8.3 percent. Two patients, representing 5.6 percent of the cohort, permanently discontinued nimotuzumab because of toxicity.

The authors were explicit about the interpretive limits of their work. In this small single-arm cohort, nimotuzumab plus concurrent chemoradiotherapy was clinically deliverable, and the observed 12-week response and preliminary two-year outcome estimates were purely descriptive. Without a concurrent CCRT-only control group, no inference can be made about the incremental efficacy of nimotuzumab, and the findings require confirmation in controlled studies. This caveat matters because single-arm trials in cancers with relatively favorable baseline response rates can appear impressive simply by enrolling patients who would have responded well to standard therapy alone.

For the field, the study provides a structured patient-level dataset for a combination that had previously lacked such documentation in EGFR-expressing locally advanced cervical squamous cell carcinoma. The reported response distribution, the sensitivity analysis handling non-evaluable patients, the survival confidence intervals, and the toxicity breakdown together offer a benchmark against which future randomized comparisons can be designed. Until such controlled studies are completed, the appropriate reading of these results is that the regimen was feasible and tolerable in this population, with outcome estimates that justify further testing rather than any claim of added benefit over standard chemoradiotherapy.

Subject of Research: A single-arm exploratory study of nimotuzumab combined with concurrent chemoradiotherapy in EGFR-expressing locally advanced cervical squamous cell carcinoma.

Article Title: Clinical outcomes and safety of nimotuzumab plus concurrent chemoradiotherapy in EGFR-expressing locally advanced cervical squamous cell carcinoma: a single-arm exploratory study

Article References: Bai, X., Zhang, H., Yan, J., Li, L., & Wu, Y. (2026). Clinical outcomes and safety of nimotuzumab plus concurrent chemoradiotherapy in EGFR-expressing locally advanced cervical squamous cell carcinoma: a single-arm exploratory study. BMC Women's Health. https://doi.org/10.1186/s12905-026-05004-x

Image Credits: AI Generated

DOI: 10.1186/s12905-026-05004-x

Keywords: nimotuzumab, cervical cancer, EGFR, concurrent chemoradiotherapy, squamous cell carcinoma, RECIST 1.1, progression-free survival, brachytherapy, adverse events, single-arm study, FIGO stage IB3–IVA, Kaplan–Meier